Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.915 USD | -5.21% | -7.45% | -8.31% |
Jun. 06 | Top Midday Decliners | MT |
Jun. 06 | Goldman Sachs Downgrades 2seventy bio to Sell From Neutral, Adjusts Price Target to $2 From $5 | MT |
Financials (USD)
Sales 2024 * | 46.91M | Sales 2025 * | 96.93M | Capitalization | 201M |
---|---|---|---|---|---|
Net income 2024 * | -142M | Net income 2025 * | -14M | EV / Sales 2024 * | 4.29 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.08 x |
P/E ratio 2024 * |
-1.43
x | P/E ratio 2025 * |
-8.4
x | Employees | 274 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.84% |
Latest transcript on 2seventy bio, Inc.
1 day | -5.21% | ||
1 week | -7.45% | ||
Current month | -7.45% | ||
1 month | -11.72% | ||
3 months | -17.06% | ||
6 months | +26.29% | ||
Current year | -8.31% |
Managers | Title | Age | Since |
---|---|---|---|
Chip Baird
CEO | Chief Executive Officer | 52 | - |
Nick Leschly
CHM | Chairman | 51 | 21-05-03 |
Susan Abu-Absi
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Daniel Lynch
BRD | Director/Board Member | 65 | 21-10-14 |
Nick Leschly
CHM | Chairman | 51 | 21-05-03 |
Chip Baird
CEO | Chief Executive Officer | 52 | - |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
2.23% | 2 M€ | -25.75% | ||
0.03% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 3.915 | -5.21% | 474,382 |
24-06-06 | 4.13 | -9.43% | 1,248,951 |
24-06-05 | 4.56 | +6.05% | 958,256 |
24-06-04 | 4.3 | +2.87% | 392,100 |
24-06-03 | 4.18 | -1.18% | 1,680,987 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.31% | 201M | |
+51.85% | 57.87B | |
+41.42% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- TSVT Stock